Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Soo, Yannie; Cheng, Yi; Wong, Raymond; Hui, David S.; Lee, C.K.; Tsang, Kenneth; Ng, Mhl; Chan, Paul K.S.; Cheng, Gregory; Sung, Joseph J.Y.

doi:10.1111/j.1469-0691.2004.00956.x

Cited by 371 publications

(401 citation statements)

References 7 publications

Supporting

Mentioning

384

Contrasting

Unclassified

Order By: Relevance

“…Convalescent plasma, donated by patients who had recovered from SARS, contains neutralizing antibodies and may be useful clinically for treating other SARS patients [126,127]. Research work in the preparation of SARS-CoV-specific hyperIg from convalescent plasma donated by patients who have recovered from SARS is currently in progress.…”

Section: Convalescent Plasmamentioning

confidence: 96%

SARS: clinical presentation, transmission, pathogenesis and treatment options

2006

View full text Add to dashboard Cite

SARS (severe acute respiratory syndrome) appeared as the first emerging infectious disease of this century. It is fortunate that the culprit virus can be grown without much difficulty from a commonly used cell line, allowing an unlimited supply of isolates for further molecular studies and leading to the development of sensitive diagnostic assays. How the virus has successfully jumped the species barrier is still a mystery. The superspreading events that occurred within hospital, hotel and high-density housing estate opens a new chapter in the mechanisms and routes of virus transmission. The old practice of quarantine proved to be still useful in controlling the global outbreak. Despite all the available sophisticated tests, alertness with early recognition by healthcare workers and prompt isolation of suspected cases is still the most important step for containing the spread of the infection. Although the rapidly evolving outbreak did not allow the conducting of systematic clinical trails to evaluate treatment options, the accumulated experience on managing SARS patients will improve the clinical outcome should SARS return. Although SARS led to more than 700 deaths worldwide, the lessons learnt have prepared healthcare systems worldwide to face future emerging and re-emerging infections.

show abstract

Section: Convalescent Plasmamentioning

confidence: 96%

SARS: clinical presentation, transmission, pathogenesis and treatment options

2006

View full text Add to dashboard Cite

show abstract

“…Although randomized placebo-controlled trials evaluating passive postexposure prophylaxis in at-risk groups have not been undertaken, a retrospective analysis of outcomes in a limited human study using plasma from convalescent SARS patients suggested that passive immunization may shorten hospitalization without obvious adverse effects in patients (171). Passive immunization has been examined in animal models.…”

Section: Passive Immunizationmentioning

confidence: 98%

The Immunobiology of SARS

Chen

Subbarao

2007

Annu. Rev. Immunol.

266

277

View full text Add to dashboard Cite

Severe acute respiratory syndrome (SARS) presented as an atypical pneumonia that progressed to acute respiratory distress syndrome in approximately 20% of cases and was associated with a mortality of about 10%. The etiological agent was a novel coronavirus (CoV). Angiotensin-converting enzyme 2 is the functional receptor for SARS-CoV; DC-SIGN and CD209L (L-SIGN) can enhance viral entry. Although the virus infects the lungs, gastrointestinal tract, liver, and kidneys, the disease is limited to the lungs, where diffuse alveolar damage is accompanied by a disproportionately sparse inflammatory infiltrate. Pro-inflammatory cytokines and chemokines, particularly IP-10, IL-8, and MCP-1, are elevated in the lungs and peripheral blood, but there is an unusual lack of an antiviral interferon (IFN) response. The virus is susceptible to exogenous type I IFN but suppresses the induction of IFN. Innate immunity is important for viral clearance in the mouse model. Virus-specific neutralizing antibodies that develop during convalescence prevent reinfection in animal models.

show abstract

“…The practice of administering polyclonal immunoglobulins isolated from hyperimmune sera of animal or human origin, introduced by Von Behring and Kitasato, has been used extensively in prophylactic as well as in therapeutic settings [158]. Passive transfer of polyclonal immunoglobulins from convalescent SARS patients was used during the SARS epidemic as a therapeutic measure and a positive effect of the therapy is reported [159,160]. However, the risks related to the use of human blood products make them problematic as a standard therapy.…”

Section: Vaccines Passive Immunizationmentioning

confidence: 98%

SARS: Understanding the Virus and Development of Rational Therapy

Stadler¹,

Rappuoli

2005

CMM

View full text Add to dashboard Cite

In late 2002 a new disease, severe atypical respiratory syndrome (SARS), emerged in China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier through close contact of humans with infected animals was identified as the etiological agent. It rapidly adapted to the new host and not only became readily transmissible between humans but also more pathogenic. Air travel spread it rapidly around the world and ultimately the virus infected 8096 people and caused 774 deaths in 26 countries on 5 continents. Aggressive quarantine measures successfully terminated the disease. Currently, there are no SARS cases recorded and most likely the virus no longer circulates in the human population. In this review we present an overview over SARS-Co virus biology, the disease and discuss strategies to develop antiviral drugs and vaccines.

show abstract

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Cited by 371 publications

References 7 publications

SARS: clinical presentation, transmission, pathogenesis and treatment options

SARS: clinical presentation, transmission, pathogenesis and treatment options

The Immunobiology of SARS

SARS: Understanding the Virus and Development of Rational Therapy

Contact Info

Product

Resources

About